GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (LTS:0QW0) » Definitions » Enterprise Value

argenx SE (LTS:0QW0) Enterprise Value : €31,615 Mil (As of Mar. 22, 2025)


View and export this data going back to 2014. Start your Free Trial

What is argenx SE Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, argenx SE's Enterprise Value is €31,615 Mil. argenx SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €82 Mil. Therefore, argenx SE's EV-to-EBIT ratio for today is 386.16.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, argenx SE's Enterprise Value is €31,615 Mil. argenx SE's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was €82 Mil. Therefore, argenx SE's EV-to-EBITDA ratio for today is 386.16.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, argenx SE's Enterprise Value is €31,615 Mil. argenx SE's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was €2,034 Mil. Therefore, argenx SE's EV-to-Revenue ratio for today is 15.54.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, argenx SE's Enterprise Value is €31,615 Mil. argenx SE's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €0 Mil. Therefore, argenx SE's EV-to-FCF ratio for today is .


argenx SE Enterprise Value Historical Data

The historical data trend for argenx SE's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Enterprise Value Chart

argenx SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,888.55 14,142.64 17,394.27 17,545.07 33,175.98

argenx SE Quarterly Data
Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17,545.07 21,763.63 21,582.11 29,135.60 33,175.98

Competitive Comparison of argenx SE's Enterprise Value

For the Biotechnology subindustry, argenx SE's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Enterprise Value distribution charts can be found below:

* The bar in red indicates where argenx SE's Enterprise Value falls into.



argenx SE Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

argenx SE's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as

argenx SE's Enterprise Value for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


argenx SE  (LTS:0QW0) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

argenx SE's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=31615.198/81.87
=386.16

argenx SE's current Enterprise Value is €31,615 Mil.
argenx SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €82 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

argenx SE's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=31615.198/81.87
=386.16

argenx SE's current Enterprise Value is €31,615 Mil.
argenx SE's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €82 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

argenx SE's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=31615.198/2034.313
=15.54

argenx SE's current Enterprise Value is €31,615 Mil.
argenx SE's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,034 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

argenx SE's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=31615.198/0
=

argenx SE's current Enterprise Value is €31,615 Mil.
argenx SE's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


argenx SE Enterprise Value Related Terms

Thank you for viewing the detailed overview of argenx SE's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


argenx SE Business Description

Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

argenx SE Headlines

No Headlines